Wczytywanie kursów wyceny...
Prognoza
| Kupuj |
4 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Check-Cap conducts 1-for-7 reverse stock split
Check-Cap will carry out a 1-for-7 reverse stock split on Wednesday, reducing outstanding common shares from about 9,463,062 to approximately 1,351,866. The common shares will remain listed on the Nasdaq Capital Market under the ticker MBAI and will be quoted adjusted for the split at the market open; the new CUSIP is M6S83C106. Fractional shares will be rounded up, and registered and brokerage-account shareholders do not need to take any action. The measure was approved by the board of directors and ratified by shareholders and is being undertaken in preparation for the planned merger with MBody AI, scheduled for Q3 2026 and still subject to Nasdaq approvals and customary closing conditions. » Więcej na de.investing.com
Check-Cap submits audited financial statements of MBody AI and targets merger for H1 2026
Check-Cap has filed financial reports with the SEC in connection with the planned merger with MBody AI and confirmed that preparations for the combination are continuing. The merger, already approved by Check-Cap shareholders on November 14, 2025, foresees MBody AI becoming a wholly owned subsidiary of Check-Cap. Check-Cap provided audited financial statements of MBody AI as of December 31, 2025, supplemented by unaudited pro forma financial information for the combined company. Closing is targeted for the first half of 2026 but is contingent on capital availability to meet NASDAQ requirements as well as regulatory and exchange reviews, with no guarantee of completion. » Więcej na de.investing.com
Check-Cap meets NASDAQ minimum capital rule after adjustment to loan receivable
Check-Cap says it now complies with NASDAQ listing rule 5550(b)(1) after restoring the collectible portion of a loan receivable from Apollo Technology Capital Corporation. According to unaudited financial statements for June 30, 2025, filed with the SEC on December 30, 2025, shareholders’ equity exceeds the required $2.5 million threshold. NASDAQ will continue to monitor compliance; delisting remains possible if Check-Cap fails to meet the rules in its next periodic report, though the company expects to be in compliance. » Więcej na de.investing.com
Check-Cap shareholders approve merger with MBody AI and name change
Shareholders of Check-Cap voted by a large majority to approve the merger with MBody AI under the agreement dated 12 September 2025, under which MBody AI will become a 100% subsidiary of Check-Cap. Also approved were a share consolidation at a ratio of 1:14 to 1:100 and the change of the company name to "MBody AI Ltd." effective on closing of the merger. The board of directors was confirmed; David Lontini remains in office as executive chairman with strong support. All resolutions reached the majorities required under Israeli law. » Więcej na de.investing.com
Check-Cap grows through merger with MBody AI after strong share gains
Check-Cap reports a definitive merger agreement with MBody AI, whose Orchestrator platform is said in the announcement to be used by global major customers. After the announcement the Check-Cap share rose sharply; the new company MBody AI Ltd. is to be 90% owned by MBody shareholders and 10% by Check-Cap shareholders. Check-Cap, with a current market capitalization of around USD 9.71 million, points to regulatory risks: the NASDAQ requires a plan to regain the minimum equity requirement by 20 October 2025, and an earnings report is due on 24 November. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | 2024 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | -154,72 tys. | 19,32% |
| Zysk netto | -24,17 mln | 52,08% |
| EBITDA | -8,94 mln | 44,01% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 9,87 mln € |
Liczba akcji | 5,85 mln |
Maksimum/minimum z 52 tygodni | 2,84 € - 0,51 € |
| Dywidendy | Nie |
Beta | 0,46 |
C/Z (PE Ratio) | 0,44 |
PEG (PEG Ratio) | 0,00 |
C/WK (PB Ratio) | 0,53 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Check-Cap Ltd., firma medyczna na etapie badań klinicznych zajmująca się diagnostyką, prowadzi prace nad technologią badań przesiewowych opartą na kapsułce, która wykorzystuje promieniowanie rentgenowskie o ultraniskiej dawce do skanowania wewnętrznej wyściółki okrężnicy w poszukiwaniu polipów przednowotworowych oraz innych nieprawidłowości strukturalnych. Jej system C-Scan składa się z C-Scan Cap, kapsułki skanującej promieniowanie rentgenowskie do wykrywania podejrzanych polipów; C-Scan Track, jednorazowego systemu mocowanego do pleców pacjenta za pomocą biokompatybilnych plastrów przylepnych; oraz C-Scan View, oprogramowania typu klient/serwer, które umożliwia pobieranie danych z procedury z C-Scan Track, analizę danych i generowanie raportów. Spółka została założona w 2004 roku i ma siedzibę w Isfiya w Izraelu.
| Nazwa | Check-Cap |
| CEO | David Lontini |
| Siedziba | Isfiya,
Izrael |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: sprzęt i produkty |
| Debiut giełdowy | 04.03.2015 |
| Pracownicy | 85 |
Deep Dive
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | CHEK |
Frankfurt | 7CC.F |
München | 7CC.MU |